Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a disease responsible for almost 1.3 million deaths per year. In recent years, different classes of drug resistant M. tuberculosis strains have emerged, making the discovery of novel anti-TB drugs a major global priority. This awareness has resulted in several new initiatives to find new (classes of) antimicrobial compounds. One of these initiatives is NM4TB, a consortium containing two noTBsec members, which discovered the benzothiazinones as promising new antimycobacterial compounds. A major disadvantage of most existing and new TB compounds is that they target a single molecule, which significantly increases the chance that resistant strains will emerge.
In this project, we will address this problem by identifying compounds that target multiple type VII secretion (T7S) systems. T7S systems are used by M. tuberculosis to secrete proteins across the cell envelope to the cell surface or into the host environment. Interestingly, this bacterium has several different T7S systems, three of which are essential for viability or virulence. We predict that, by blocking multiple T7S systems with a single compound, we will considerably reduce the development of drug resistance. To target T7S systems, we will use two complementary approaches to identify: (i) secretion blockers based on secretion activity assays and (ii) compounds designed to target specific T7S components.
As proof of principle, we have already successfully used the first approach to identify two different classes of compounds that block T7S systems. Importantly, one of these compounds significantly reduced mycobacterial growth in vivo. For the second approach we will exploit the detailed knowledge of T7S systems that has been recently generated within the consortium, including structures of several crucial druggable components. To increase the activities of our secretion-blocking compounds, we will also identify compounds that act synergistically with them from libraries of antibiotics and other FDA-approved drugs. Subsequently (combinations of) compounds will be tested in vivo in a high throughput animal model for activity, toxicity and resistance development. Together, these experiments will identify molecules inhibiting T7S secretion. These will be used to test the concept that by inactivating multiple essential targets, the emergence of drug resistance is reduced.
- Willbert Bitter, VU University Medical Center, Netherlands (Coordinator)
- Roland Brosch, Pasteur Institute, France
- Magnus Steigedal, Norwegian University of Science and Technology, Norway
- Charles Thompson, University of British Columbia, Canada
- Stewart Cole, Swiss Federal Institute of Technology Lausanne (EPFL), Switzerland
- Plos Neglected Tropical Diseases, 2019. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
- Antimicrobial Agents and Chemotherapy, 2018. Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination
- Cell Reports, 2018. Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis secrected proetien effectors
- Infection and Immunity, 2018. Genetic Variation/Evolution and Differential Host Responses Resulting from In-Patient Adaptation of Mycobacterium avium
- PNAS, 2018. Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions
- Nature Microbiology, 2018. Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis
- Plos Pathogens, 2018.RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection
- Cellular Microbiology, 2017. ESX‐1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis
- Antimicrobial Agents and Chemotherapy, 2017. Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the whiB7 Gene
- Molecular Microbiology, 2017. Regulatory genes coordinating antibiotic‐induced changes in promoter activity and early transcriptional termination of the mycobacterial intrinsic resistance gene whiB7
- Plos Genetics, 2017. Cell envelope stress in mycobacteria is regulated by the novel signal transduction ATPase IniR in response to trehalose
- Cell Reports, 2017. Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection
- Molecular Microbiology, 2016. Discovery of the type VII ESX‐1 secretion needle?
- Scientific Reports 2016. Repurposing clinically approved cephalosporins for tuberculosis therapy
- Journal of Biological Chemistry, 2016. iniBAC induction Is Vitamin B12- and MutAB-dependent in Mycobacterium marinum
- PNAS, 2016. Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria
- Nature REviews Microbiology, 2016. ESX secretion systems: mycobacterial evolution to counter host immunity
- Plos One, 2015. Benzoic Acid-Inducible Gene Expression in Mycobacteria